The cellular redox state has been increasingly recognized as a critical component of stress-induced cellular responses and disease. Inherent in these responses are reactive oxygen species (ROS), including • O 2 Ϫ , H 2 O 2 , and • OH, which inflict direct cellular damage in addition to acting as intracellular second messengers modulating signal transduction pathways. These intracellular highways of communication are critical in determining cell fates and whole-organ responses following environmental injury. Pathologic events caused by transient tissue hypoxia followed by oxygen reperfusion (ischemic/reperfusion [I/R]) are the cause of numerous types of surgical and environmentally induced injuries in the liver associated with transplantation and resection. Pathologic changes encountered following reperfusion of an ischemic organ include the immediate generation of ROS, as well as subsequent neutrophil-predominant inflammatory responses that lead to a second round of deleterious ROS generation at sites of damage. Recently, it has become increasingly appreciated that ROS are involved as second messengers in a number of cellular signaling events leading to the induction of AP-1 and nuclear factor-B pathways.
The cellular redox state has been increasingly recognized as a critical component of stress-induced cellular responses and disease. Inherent in these responses are reactive oxygen species (ROS), including • O 2 Ϫ , H 2 O 2 , and • OH, which inflict direct cellular damage in addition to acting as intracellular second messengers modulating signal transduction pathways. These intracellular highways of communication are critical in determining cell fates and whole-organ responses following environmental injury. Pathologic events caused by transient tissue hypoxia followed by oxygen reperfusion (ischemic/reperfusion [I/R]) are the cause of numerous types of surgical and environmentally induced injuries in the liver associated with transplantation and resection. Pathologic changes encountered following reperfusion of an ischemic organ include the immediate generation of ROS, as well as subsequent neutrophil-predominant inflammatory responses that lead to a second round of deleterious ROS generation at sites of damage. Recently, it has become increasingly appreciated that ROS are involved as second messengers in a number of cellular signaling events leading to the induction of AP-1 and nuclear factor-B pathways. [1] [2] [3] These pathways are important in determining cellular fates involved in organ remodeling (apoptosis and regeneration) and recruitment of inflammatory cells to the damaged tissue.
The pathophysiology of I/R injury in the liver has been demonstrated to occur in a biphasic pattern. There is an initial acute phase characterized by hepatocellular damage at 3 to 6 hours, and a subacute phase characterized by massive neutrophil infiltration at 18 to 24 hours. 4, 5 The mechanisms of liver damage following I/R are thought to involve a complex interaction of acute cellular damage caused by ROS, 6, 7 detrimental cellular responses resulting from tumor necrosis factor ␣ and interleukin-1 released by Kupffer cells , and subacute leukocyte recruitment that further exacerbates liver injury. 4, 8, 9, 10 Numerous studies suggest that oxygen-free radical formation following reoxygenation may initiate the cascade of hepatocellular injury, necrosis/apoptosis, and subsequent inflammatory infiltration. 6, [11] [12] [13] Free radicals produced following I/R can lead to oxidative damage of DNA, proteins, and lipids, which contribute to cellular dysfunction or can directly regulate signal transduction. All of these redox-sensitive pathways can ultimately affect liver remodeling following injury through the production of cytokines and growth factors. Therefore, therapeutic approaches aimed at reducing oxidative stress have been traditionally thought to be a rational therapeutic strategy for decreasing the complications associated with I/R damage. However, despite the vast number of experimental reports evaluating the effects of I/R in the liver, the precise mechanism leading to the ultimate decline in liver function and eventual organ failure remains elusive.
Sources of ROS formation following liver I/R remain controversial and may involve Kupffer cells, hepatocytes, endothelial cells, and/or neutrophils. Moreover, the relative contribution of ROS production by hepatocytes, reticular endothelial cells, and/or neutrophils in the pathogenesis of I/R injury is still poorly understood. However, one important type of ROS shown to be involved in I/R injury is superoxides. 5, 12, 14, 15 Several mechanisms have been proposed for the generation of superoxides during both the acute and subacute phases of I/R, including: 1) the xanthine/xanthine oxidase system, 2) mitochondrial respiration, 3) receptor-induced ROS generation by pathways such as Rac1/NADPH oxidase, and 4) inflammatory cell production of superoxides. 16, 17 Endogenous cellular defenses against superoxide production involve a set of superoxide dismutase (SOD) genes expressed in unique subcellular compartments. SODs catalyze the dismutation of • O 2 Ϫ to yield H 2 O 2 and O 2 . The 3 forms of SODs have different subcellular localizations. These include Cu/Zn-SOD 18 and MnSOD, 19 which reside in the cytoplasm or mitochondria, respectively. However, some reports have suggested that Cu/ZnSOD may also reside in the nucleus, peroxisomes, and lysosomes. [20] [21] [22] A third form, ecSOD, 23 is secreted into the extracellular environment.
AP-1 is a widely recognized redox-activated transcription factor important in I/R damage to the liver. The family of AP-1 transcription factors is subdivided into 3 main subgroups: the Jun proteins (v-Jun, c-Jun, JunB, JunD), the Fos family members (v-Fos, c-Fos, FosB, Fra1, Fra2), and the activating transcription factors (ATF2, ATF-3, B-ATF), which can form homodimers and/or heterodimers with other AP-1 members. 24 This group of proteins has been shown to be extremely important in regulating stress response genes controlling proliferation and programmed cell death. 24 AP-1 activity is regulated at 2 major levels: both by the abundance and type of the AP-1 proteins, and by posttranslational modifications altering DNA binding and transactivation activity. 25, 26 Redox modulation of AP-1 predominantly occurs through 3 mechanisms involving posttranslational modifications. First, the phosphorylation of c-Jun can be controlled by redox activation of c-Jun NH 2 -terminal kinases (JNK). 27, 28 Phosphorylation of cJun at serine 63 and 73 by JNK can affect the transcriptional activity of the AP-1 complex by either directly altering its transactivation potential and/or altering its binding partners in the AP-1 dimer complex. There are 3 different genes that encode JNK protein kinases: JNK1, JNK2, and JNK3, and all also give rise to alternatively spliced isoforms. 29 These isoforms have different binding affinities for the members of the AP-1 transcription factor family and can thereby selectively target and activate specific AP-1 subunits. A second mechanism of redox regulation of AP-1 involves a posttranslational mechanism of reduction-oxidation at a conserved cysteine residue found in the DNA binding domain of Fos and Jun. 30 Such reduction-oxidation reactions are regulated by a ubiquitous nuclear redox factor (Ref-1). 31 Transcription of this DNA repair enzyme is induced by a number of redox-mediated environmental insults such as hypoxia. 32 Ref-1-mediated reduction of redox-sensitive cysteines within c-Jun and c-fos stimulates DNA binding, whereas oxidation inhibits DNA binding activity. Such findings have implicated accessory redox-related genes in the control of AP-1 transcriptional activity during cellular stress. A third potential level of posttranscriptional regulation of AP-1 activity occurs through PI3-kinase/PKB/GSK3 regulatory pathways. In this pathway, GSK mediates phosphorylation of c-Jun near its DNA binding domain, thus inhibiting c-Jun DNA binding, and thus AP-1 activation. 33 Recently, redox-modulating gene therapy has been applied to models of I/R injury in the liver and has demonstrated great promise in attenuating hepatocellular damage. 15 This approach has utilized recombinant adenovirus encoding the human MnSOD gene. These studies demonstrated that expression of MnSOD attenuated both hepatocellular I/R damage and activation of both AP-1 and nuclear factor-B transcription factors. In the present study, we sought to compare the therapeutic effects of MnSOD and Cu/ZnSOD gene expression in preventing I/R liver damage using recombinant adenoviral vectors. We hypothesized that redox-mediated hepatocellular responses following I/R injury might be regulated at the subcellular level by partitioning of superoxides to various sites within the cell. Findings from this study support this hypothesis and demonstrate that superoxide clearance in the cytoplasm (by expression of Cu/ZnSOD) has drastically different effects on activation of AP-1 before and following I/R injury when compared with expression of MnSOD. Furthermore, MnSOD, but not Cu/ZnSOD, expression was capable of significant protection from hepatocellular damage following I/R injury. These studies support the fact that the subcellular compartmentalization of superoxides is important in controlling AP-1 activation and hepatocellular responses to I/R injury.
MATERIALS AND METHODS
Mouse Model of Warm Lobar I/R Injury. Male (25 g) nu/nu athymic BALB/c mice (Harlan Sprague-Dawley) were used for partial lobar liver I/R experiments as previously described. 15, 34 Protocols were in accordance with the National Institutes of Health Animal Guidelines. In brief, mice were anesthetized with ketamine/xylazine and a laparotomy was performed to expose the largest, medial lobe of the liver. Following surgical exposure of the liver, mice were injected with heparin (100 g/kg) to prevent clotting of blood during ischemia. The medial lobe of the liver was clamped at its base using a microaneurysm clamp, followed by placement of the liver and clamp back into the peritoneal cavity for 60 minutes. Following surgically implemented ischemia, the micro-aneurysm clamp was removed, the abdominal wall was sutured, and the animals were returned to their cages. Serum transaminase levels (international units/liter of alanine transaminase [ALT]) were measured from retro-orbital blood samples (harvesting 25 L blood) before I/R and at 3, 6, and 20 hours after the initiation of reperfusion, using a microkinetic assay (2-6 L of serum) as previously described. 15 Livers were also harvested at 3 hours after the initiation of reperfusion for preparation of nuclear extracts and evaluation of AP-1 and JNK activity.
Gene Delivery to the Liver With Recombinant Adenovirus. Recombinant adenoviruses encoding the human MnSOD, 35 Cu/ZnSOD, 35 Catalase, 36 and LacZ 15 genes were used in the described studies. All viruses designated Ad.MnSOD, Ad.Cu/ZnSOD, Ad.Catalase, and Ad.LacZ, contained the respective transgenes under the direction of the cytomegalovirus promoter/enhancer and SV40 polyadenylation signal. Purified high-titer stocks (0.5-2 ϫ 10 13 particles/mL) of recombinant adenovirus were generated by 2 sequential rounds of CsCl 2 banding and desalted by gel-filtration in phosphate-buffered saline (PBS) on a Sephadex G-50 column just before use, as previ-ously described. 37 Viral infections were performed 14 days before liver I/R surgery by tail-vein injection with 10 11 particles per 25 g body weight of the purified virus in 200 L of PBS. When coinfection experiments were performed with Ad.Catalase and/or Ad.Cu/Zn-SOD, the dose of each virus used was 5 ϫ 10 10 particles per 25 g body weight. Mock-infected animals were injected with an equivalent about of PBS without virus. Viral titers were checked by plaque assays on 293 cells and demonstrated a particle:pfu ratio of approximately 20:1. All viral stocks were free from wild-type adenovirus as assayed by polymerase chain reaction for the adenoviral E1 gene and replication assays on permissive cell lines (sensitivity of Ͻ1 wildtype particle in 10 10 recombinant particles).
Gene-Transfer Experiments in Hepatocytes and Macrophage Cell Lines.
Two cell lines were used to evaluate AP-1-inductive mechanisms in hepatocytes and macrophages in vitro. TIB73 cells were used as a model of mouse hepatocytes, and RAW 264.7 cells were used as a mouse macrophage model of Kupffer cells. Recombinant Ad.Cu/ ZnSOD, Ad.MnSOD, and Ad.LacZ were used to infect TIB and RAW cells at multiplicities of infection of 1,000 and 10,000 particles per cell, respectively. In initial experiments, cells were infected with recombinant adenovirus 48 hours before the preparation of nuclear extracts for AP-1 analysis. A second experimental approach was used to evaluate potential Cu/ZnSOD-induced paracrine mechanisms involved in the activation of AP-1. In these studies, TIB or RAW cells were either mock-infected or infected with Ad.Cu/ZnSOD for 24 hours, followed by a media change and continued incubation for an additional 24 hours. Conditioned media from mock-infected or Ad.Cu/ZnSOD-infected cells were then harvested 24 hours later and placed on either uninfected or Ad.Cu/ZnSOD-infected reciprocal cell lines. Nuclear extracts were then prepared after a 24-hour exposure to conditioned media.
Assays for Transgene Expression. SOD enzymatic activity was measured in native acrylamide gels as previously described. 15 Livers were perfused with saline containing 0.05% heparin to remove excess blood cells that might contain SOD activity, and homogenized in 1 mL of 50 mmol/L potassium phosphate buffer (pH 7.8). Lysates were centrifuged at 4,500g for 10 minutes, and the supernatants were collected. Protein content was measured by Bradford assay (BioRad), and 200 g were separated on a native, nondenaturing 12% polyacrylamide gel electrophoresis (PAGE). The gels were incubated in 2.45 mmol/L Nitro-blue tetrazolium chloride in distilled water for 20 minutes, followed by an additional 15-minute incubation in 50 mmol/L potassium phosphate buffer (pH 7.8), containing 2.8 ϫ 10 Ϫ5 mol/L riboflavin and 28 mmol/L N,N,NЈNЈ-tetramethylethylenediamine (TEMED) to detect total SOD activity. To stain for MnSOD alone, 0.75 mmol/L NaCN was included in the NBT and riboflavin-TEMED solutions. Both incubations were performed at room temperature in the dark. Following staining, gels were washed in distilled water. Enzymatic activity is noted as regions of clearing in a background of black precipitate. To confirm recombinant catalase expression in the liver, native gel Western blotting was used as previously described. 36 Liver lobes were washed twice in PBS and homogenized in 2 mL of buffer (0. . The protein content of the liver extracts was measured by Bradford assay (BioRad, Hercules, CA), and 200 g was separated on a nondenaturing 8% PAGE. The proteins were then transferred to nitrocellulose membrane (HybondC, Amersham, Piscataway, NJ) overnight. The membrane was stained with 0.5% PonceauS to check for efficient transfer and subsequently blocked in 4% nonfat dry milk solution in PBS, supplemented with 0.3% Tween20. This solution was used for all other antibody incubations and washing steps. Sheep primary antibody directed against human catalase (The Binding Site Inc., San Diego, CA Cat# PC136) was diluted 1:2,000 and detected with anti-sheep horseradish peroxidase antibody (Sigma, St. Louis, MO) at a 1:2,000 dilution using an ECL system (Amersham).
To assess the extent of hepatocyte and Kupffer cell infection in the liver with recombinant adenovirus, a ␤-galactosidase reporter geneand Kupffer cell-specific marker (Ly-71) were used. Colocalization of ␤-galactosidase and Ly-71 were performed on mouse liver frozen sections at 72 hours' postinfection with Ad.LacZ. Five-micrometer frozen sections were cut and fixed in 4% paraformaldehyde for 15 minutes, followed by postfixation in Ϫ20°C methanol for 10 minutes. Sections were then air-dried and blocked in 20% goat serum/ PBS for 1 hour. Slides were incubated with a 1:100 dilution of a fluorescein isothiocyanate (FITC)-conjugated rat monoclonal antibody to mouse F4/80 (macrophage, Ly-71) (Caltag Laboratories, Burlingame, CA; product code RM2901) at 4°C overnight. After 3 washes in 1.5% goat serum/PBS, slides were incubated with a 1:100 dilution of a rabbit antibody to ␤-galactosidase (5 prime-3 prime, Inc., Boulder, CO; catalog # 5307-063100) for 1 hour. This was followed by 3 washes in 1.5% goat serum/PBS and incubation with a 1:150 dilution of a Texas Red-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) for 30 minutes. Sections were visualized by fluorescent microscopy under Texas Red-and FITC-specific filters.
Subcellular Fractionation of Cytoplasmic, Mitochondrial, and Nuclear Extracts. To confirm that adenoviral overexpression of human Cu/Zn-SOD and MnSOD correctly localize to cytoplasmic and mitochondrial compartments, respectively, we performed Western blots on subcellular fractions isolated from adenovirally infected livers. Animals were infected with Ad.Cu/ZnSOD or Ad.MnSOD using the methods described above. Seventy-two hours' postinfection, livers were cooled on ice cold and homogenized in 4mL of iodixanol buffer
Homogenates were filtered through 3 layers of cheesecloth and centrifuged at 2,250 rpm in a table-top centrifuge for 10 minutes at 4°C. Pellets contain crude nuclear fractions, while supernatants contain all other organelles in the crude cytoplasmic fraction. Crude nuclear fractions were purified by resuspending to a final concentration of 25% iodixanol, top-loaded onto a 30% and 36% step gradient of iodixanol, and centrifuged at 10,000 rpm in a SW41 rotor for 2 hours. Purified nuclei appeared at the interface of 30% and 36% iodixanol. Organelles were separated from the crude cytoplasmic fraction by centrifugation at 10,900 rpm in a NVT90 rotor for 30 minutes. The supernatants contain the final cytoplasmic fraction. The pellets, which contain mitochondria and other organelles, were resuspended in 1.4 mL of iodixanol buffer A and adjusted to 36% iodixanol by adding 3.6 mL of a 50% iodixanol working solution (mix 5 volumes of OptiPrep, Nycomed Pharm with 1 volume of 0.25 mol/L sucrose, 10 mmol/L EDTA, 60 mmol/L HEPES [pH 7.4]). These crude organelle fractions were layered with 10% and 30% iodixanol and centrifuged at 20,500 rpm in a SW41 rotor for 4 hours. Purified mitochondrial fractions banded at a density of 1.13 to 1.15 g/mL and were collected. Western blots were performed on each of the various fractions (crude lysate, cytoplasmic fraction, mitochondrial fraction, and nuclear fraction) using a polyclonal rabbit antihuman MnSOD antibody 38 and a polyclonal sheep anti-human Cu/ ZnSOD (The Binding Site; code number pc077). Total protein content was quantitated by the Bradford assay (BioRad) and 75 g (for Cu/ZnSOD detection) or 5 g (for MnSOD detection) separated by denaturing 12% sodium dodecyl sulfate (SDS)-PAGE, followed by electroblotting to nitrocellulose membrane. The membranes were incubated with primary antibodies (1:5,000 for MnSOD, 1:2,000 for Cu/ZnSOD), followed by incubation with horseradish peroxidaseconjugated goat anti-rabbit IgG (Sigma) or donkey anti-sheep IgG (Sigma) (1:2,000). Detection by the chemiluminescence reaction was peformed for 2 minutes using an ECL kit (Amersham, UK), followed by exposure to Kodak X-OMAT X-ray film (Eastman Kodak, Rochester, NY).
Electrophoretic Mobility Shift Assays for AP-1 DNA Binding. Nuclear extracts from the liver were generated as previously described. 15 A Bradford assay (Biorad) was used to measure the protein content of purified nuclei and the concentrations of all samples adjusted to 1 g/L using Dignam C solution. Six microliters of nuclear extract was incubated in electrophorectic mobility shift assay (EMSA) buffer (250 mmol/L KCl, 100 mmol/L HEPES [pH 7.9], 25% glycerol, 5 mmol/L EDTA, 5 mmol/L dithiothreitol) with bovine serum albumin (1 g/L), poly (dI-dC) (1 g/L), and double-stranded, 32 P endlabeled oligo (200,000 cpm) in a total volume of 20 L. This mixture was incubated for 30 minutes at room temperature and separated on a 4% native polyacrylamide gel run with Tris/glycine buffer (125 mmol/L Tris [pH 8.5], 950 mmol/L glycine, 5 mmol/L EDTA). The oligo sequence used for the AP-1 double-stranded probe was 5Ј-CGCTTGATGACTCAGCCGGAA-3Ј. Supershift assays were similarly performed, but nuclear extracts were preincubated with the following antibodies before the DNA binding reaction: anti-c-Jun (100 g/mL; Santa Cruz, cat# sc-45GX), anti-JunD (100 g/mL; Santa Cruz, cat# sc-74GX), anti-JunB (100 g/mL; Santa Cruz, cat# sc-46GX).
JNK Activity Assays. JNK activity was evaluated using an immune complex protein kinase assay with slight modification to a previously described protocol. 39 Briefly, JNK-1 was immunoprecipitated from 300 g of whole-cell liver protein extract in 300 L of ice-cold RIPA buffer (0.15 mol/L NaCl, 50 mmol/L Tris [pH7.2], 0.5% sodium deoxycholate, 0.1% SDS, 1% IGEPAL CA630 (Sigma Chemicals), 1 mmol/L phyenylmethylsulfonyl fluoride, 1 mmol/L sodium orthovanadate, 30 L/mL aprotinin). Twenty micrograms of an agarose-conjugated polyclonal antibody that specifically recognizes a 46-kd form of JNK-1 was added to cell lysates, and the mixture was incubated overnight while rotating at 4°C. The agarose beads were then washed 4 times with ice-cold RIPA buffer and finally resuspended in 1ϫ kinase buffer. In vitro kinase reactions in the presence of ␥-ATP 32 and SDS-PAGE autoradiography were performed exactly as previously described by this laboratory. 39 Gadolinium Chloride Ablation of Kupffer Cells. In vivo Kupffer cell depletion was performed using a previously reported protocol. 40 Athymic mice were infected with recombinant viruses, and on consecutive days 11-13, postinfection were injected (3 injections in total) with gadolinium chloride (GdCl 3 ) at 7mg/kg in PBS via the tail vein. On day 14, the livers were harvested for the preparation of nuclear extracts or performing in vivo colloidal carbon uptake assays. This experimental design enabled the evaluation of AP-1 activity in Kupffer cell-depleted livers in which hepatocytes expressed the Cu/ ZnSOD transgene. In a second set of experiments attempting to ablate Kupffer cells before adenoviral infection, animals were treated with GdCl 3 for 3 consecutive days just before adenoviral infection with Ad.Cu/ZnSOD. Animals were subsequently evaluated on day 17 for AP-1 activity. This experimental design enabled the evaluation of AP-1 activity in livers containing Kupffer cells that did not express the transgene, and hepatocytes that did express the Cu/ZnSOD transgene. To confirm that Kupffer cells had regenerated within the 14-day window before analysis of AP-1 DNA, a set of control animals were depleted of Kupffer cells on day 1-3 and subsequently infected with Ad.Cu/ZnSOD on day 17, and evaluated for AP-1 activity on day 31. This control was used as a reference for the availability of Kupffer cells (on day 17), which are required for the full AP-1-inducible response following Ad.Cu/ZnSOD infection.
In Vivo Colloidal Carbon Uptake Assays. Colloidal carbon uptake assays were performed on athymic mice at 14 days' postinfection with recombinant adenovirus. Fifteen minutes after injection of 4 mg/100 L of Black India Ink (Design Higgins, Eberhard Faver, Inc., Lewisburg, TN) in 1% gelatin in water through the tail vein, liver samples were collected, fixed, and embedded in OCT. Five-micrometer frozen sections were cut, coverslipped immediately with Aqua-Mount, and examined under dark field to assess the colloidal carbon uptake. Morphometric analysis for colloidal carbon in the liver was performed by digitizing dark-field photomicrographs and quantifying the area of grains as a percentage of the entire field using NIH image software. The fraction of grain area in the liver was used to calculate the index of colloidal carbon uptake (area of grains/area of section).
In total, five 10ϫ fields were analyzed from each animal, and 4 independent animals were analyzed for each experimental point.
RESULTS

Ectopic Expression of MnSOD, but Not Cu/ZnSOD, Protects the
Liver From Warm I/R injury. Studies evaluating adenoviral-mediated gene transfer of MnSOD to the liver have demonstrated the ability of this transgene to inhibit I/R injury. 15 These studies also demonstrated a direct correlation between MnSODmediated protection and attenuation of AP-1 activation following I/R injury. Although no direct causal link between AP-1 and acute damage could be concluded from these studies, they did imply that the level of AP-1 activation is involved in acute redox-regulated cellular responses to I/R injury. In the present study, we sought to determine whether cytoplasmic and mitochondrial subcellular compartments play unique redox roles in the regulation of this AP-1 response to I/R injury in the liver. Specifically, we asked whether superoxide clearance by Cu/ZnSOD or MnSOD would have similar functional benefits in reducing I/R damage and AP-1 activation.
As previously demonstrated, 15 adenoviral-mediated expression of MnSOD in the liver, before partial lobar I/R injury, imparted significant protection from acute liver damage as assessed by serum levels of ALT (Fig. 1A) . In contrast, expression of the cytoplasmic form of SOD (Cu/ZnSOD) gave a similar ALT injury-response profile as seen in uninfected and Ad.LacZ-infected control animals (Fig. 1A) . Enzyme activity gels for both MnSOD and Cu/ZnSOD demonstrated similar extents of transgene expression with Ad.MnSOD and Ad.Cu/ ZnSOD vectors, respectively (Fig. 1B) . Given the previous characterization of these 2 vectors demonstrating that Mn-SOD and Cu/ZnSOD transgene expression is confined to the mitochondria and cytoplasm, respectively, 35 these studies indicate that mitochondrial superoxides play a more important role in mediating protection from warm I/R injury in the liver.
To confirm that ectopic overexpression of both human Cu/ ZnSOD and MnSOD did not alter the predicted subcellular localization of these proteins in the liver, biochemical subcellular fractionation and Western blot experiments were performed on Ad.Cu/ZnSOD-and Ad.MnSOD-infected livers. As shown in Fig. 1C , Western blots of cytoplasmic, mitochondrial, and nuclear fractions probed with anti-Cu/ZnSOD antibody (which recognized the mouse and human forms equally) demonstrated that the adenovirally overexpressed hCu/Zn-SOD protein partitioned to the cytoplasmic fraction in an identical distribution as the native mCu/ZnSOD protein seen in Ad.MnSOD-infected livers (compare lanes 2 and 6, Fig.  1C ). No expression of either the transgene-derived or native Cu/ZnSOD protein partitioned to the mitochondrial or nuclear fractions. Similarly, the distribution of adenovirally expressed hMnSOD was confined to the mitochondrial fractions, with no expression in either the cytoplasmic or nuclear fractions. These results confirm the correct distribution of ectopically expressed hCu/ZnSOD and hMnSOD proteins in the liver to cytoplasmic and mitochondrial fractions, respectively. Furthermore, the level of overexpression achieved closely mirrored that seen in enzyme activity gels (Fig. 1B) .
Cu/ZnSOD and MnSOD Expression Differentially Affect AP-1
Activation. We next sought to evaluate the extent of AP-1 activation following I/R injury under conditions in which superoxide clearance in mitochondria and cytoplasm were enhanced. These studies (Fig. 2) demonstrate that Ad.MnSOD infection in the liver before I/R injury significantly attenuated AP-1 induction. In contrast, Ad.Cu/ZnSOD infection only slightly attenuated AP-1 activation to a much lesser extent than that seen following Ad.MnSOD infection. No significant alteration in AP-1 activity was seen in Ad.LacZ-infected livers following I/R as compared with uninfected controls (Fig. 2A) . Interestingly, when the baseline level of AP-1 activity was assessed in animals infected with the various recombinant adenoviral vectors before I/R injury, it was observed that Cu/ ZnSOD expression significantly elevated preischemic levels of AP-1 DNA binding (Fig. 2B, lanes 14 and 15) . This effect was observed as early as 3 days' postinfection with Ad.Cu/ZnSOD (data not shown) and was not observed in animals infected with either Ad.LacZ or Ad.MnSOD vectors. Thus, these studies suggested that the inability of ectopic Cu/ZnSOD expression to significantly attenuate AP-1 activation following I/R injury may be a consequence of altered baseline levels of AP-1 activity rather than an inherent effect associated directly with the I/R response.
Given the differences in the ability of MnSOD and Cu/ ZnSOD expression to modulate AP-1 activity before and following I/R injury, we next sought to evaluate whether the Cu/ZnSOD-activated AP-1 complex was composed of different or similar subunits as seen following I/R injury. Previous studies have demonstrated that I/R injury promotes activation of AP-1 complexes composed predominantly of both JunD and c-Jun. 15, 39 To compare components of the AP-1 complex that were activated by I/R injury or ectopic expression of Cu/ ZnSOD in the liver, we performed EMSA supershift analyses. These results, presented in Fig. 3A , demonstrated that both JunD and c-Jun were major components of the AP-1 complex following either I/R injury or Cu/ZnSOD ectopic expression. Such information suggests that AP-1 activation by Cu/ZnSOD ectopic expression may produce a functionally similar AP-1 complex as seen following I/R injury in the liver.
Cu/ZnSOD-Induced AP-1 Activation Occurs in the Absence of JNK Activation. AP-1 activation in the liver after I/R injury is regulated at least in part by activation of c-Jun NH 2 -terminal kinase (JNK), which mediates phosphorylation of c-Jun at serine 63 and 73. 39, 41 We also sought to determine whether ectopic expression of Cu/ZnSOD in the liver mediated AP-1 activation through the JNK pathway. As shown in Fig. 3B , in vitro kinase assays for JNK-1 activity using a GST-c-Jun substrate demonstrated minimal changes in JNK-1 activity in liver cellular extracts from animals infected with Ad.Cu/ ZnSOD in comparison with PBS-injected controls (Fig. 3B) . A slight elevation in JNK activity following Ad.Cu/ZnSOD infection was seen at 1 week postinfection, which returned to baseline levels by 2 weeks. This was contrasted to the significantly increased levels of JNK-1 activity seen in livers following I/R injury (Fig. 3B) . In summary, these results suggest that AP-1 activation under conditions of elevated Cu/ZnSOD expression likely occurs through a pathway independent of the JNK/SAPK pathway previously characterized to be induced following both warm and cold I/R injury. 42, 43 These same studies suggested that AP-1 is only weakly activated directly by H 2 O 2 , 42 while others have demonstrated that H 2 O 2 is a potent activator of AP-1 in endothelial cells. 44 The apparent discrepancy of these results was in part clarified by studies characterizing ROS intermediates with EPR spectroscopy following butylated hydroxyanisole (BHA) and PDTC treatment of HepG2 cells and correlating ROS levels with AP-1 induction. 45 It was demonstrated that the auto-oxidation of compounds such as BHA and PDTC leads to an increase in • OH radicals, and that exogenous catalase expression could inhibit the rate and amount of • OH radical formation and the induction of AP-1 pathways. These FIG. 1. Ectopic expression of MnSOD, but not Cu/ZnSOD, attenuates liver damage following I/R. Athymic BALB/c mice were infected with recombinant adenoviruses Ad.MnSOD, Ad.Cu/ZnSOD, Ad.LacZ, or PBS 2 weeks before 60 minutes of partial lobar ischemia, followed by reperfusion for 20 hours. Serum samples were assayed for ALT (0 hour baseline) before ischemia, and after 3, 6, and 20 hours of reperfusion (A). Results depict the mean (ϮSEM) for 4 independent animals in each vector group. Functional expression of MnSOD and Cu/ZnSOD was assessed in these animals using an in-gel enzyme assay (B). Two representative liver samples are shown for each vector using gel assay conditions in the absence of cyanide. The position of recombinant human MnSOD, endogenous mouse Cu/ZnSOD, and recombinant human Cu/ZnSOD are marked by arrows to the left of the gel. Similar gels processed in the presence of cyanide inhibited all Cu/ZnSOD activity (data not shown). To demonstrate the correct partitioning of adenovirally expressed hCu/ZnSOD and hMnSOD to either cytoplasmic or mitochondrial compartments, respectively, subcellular fractionation experiments were performed on infected livers (C). Whole-cell lysates (lanes 1 and 5) , cytoplasmic fractions (lanes 2 and 6), mitochondrial fractions (lanes 3 and 7), and nuclear fractions (lanes 4 and 8) were separated by SDS-PAGE, and Western blot analysis was performed against Cu/ZnSOD (top blot) or MnSOD (bottom blot) antibodies using ECL detection. results suggest that the formation of H 2 O 2 in the metabolism of these supposed antioxidants (BHA and PDTC) may in fact lead to a pro-oxidant state responsible for AP-1 activation. To investigate whether overexpression of Cu/ZnSOD could also lead to a pro-oxidative state through the catalytic generation of H 2 O 2 , we hypothesized that overexpression of catalase in vivo using a recombinant adenoviral vector would abrogate the increased level of AP-1 induction caused by ectopic expression of Cu/ZnSOD. To this end, we compared the level of AP-1 induction in livers infected with either Ad.Cu/ZnSOD, Ad.Catalase, or coinfected with Ad.Cu/ZnSOD and Ad.Catalase. Results from these experiments (Fig. 4) demonstrate that coexpression of catalase with Cu/ZnSOD can significantly attenuate AP-1 induction in comparison with Cu/ZnSOD expression alone. In contrast, expression of catalase alone had no obvious effect on AP-1 activity. These findings support the notion that H 2 O 2 , or a conversion product such as • OH radicals, produced by Cu/ZnSOD overexpression may in fact be responsible for mediating increased AP-1 activation.
Kupffer Cells Are Required for Cu/ZnSOD-Mediated Induction of AP-1 in the Liver. To further elucidate the cellular components in the liver responsible for AP-1 induction by excessive Cu/ZnSOD expression, we investigated whether ablation of Kupffer cells in Cu/ZnSOD-overexpressing livers could alter the extent of AP-1 induction. These studies used GdCl 3 treatment to ablate hepatic Kupffer cells 40 after infection with Ad.Cu/ZnSOD and before analysis of AP-1 DNA binding activity. Results from these studies are presented in Fig. 5A and clearly demonstrated that GdCl 3 treatment for 3 consecutive days significantly attenuated AP-1 activation in livers infected with Ad.Cu/ZnSOD in comparison with untreated controls. Quantification of DNA-binding activity by densitometry demonstrated that GdCl 3 treatment of Ad.Cu/ZnSOD-infected livers reduced AP-1 induction 4-fold; however, the activity of AP-1 DNA binding still remained above the background level of uninfected livers (Fig. 5B) . These findings suggest several possibilities for the involvement of Kupffer cells in Cu/ZnSODmediated induction of AP-1. First, it is obvious that the presence of Kupffer cells in the liver is required for induction of AP-1. However, it remains unclear whether AP-1 induction is occurring in hepatocytes and/or Kupffer cells. Second, it is also unclear whether both hepatocytes and Kupffer cells must overexpress the Cu/ZnSOD transgene to obtain full induction of AP-1. To begin to address some of these mechanistic aspects, we further refined our in vivo experiments to investigate whether AP-1 induction re- quired expression of Cu/ZnSOD in both Kupffer cells and hepatocytes.
Although it is beyond the feasibility of current recombinant adenoviral vectors to target specific subpopulations of liver cells (i.e., hepatocytes vs. Kupffer cells), using Kupffer cell depletion before adenoviral infection, we were able to design an experimental protocol in which livers expressed hCu/ ZnSOD primarily in hepatocytes, but not Kupffer cells. Livers expressing hCu/ZnSOD primarily in hepatocytes, but not Kupffer cells, were generated by pretreating animals with GdCl 3 for 3 days before infection with Ad.Cu/ZnSOD. Sufficient time was then allowed for Kupffer cells to repopulate the liver by waiting for an additional 14 days before evaluation of AP-1 activity. As shown in Fig. 5C (lanes 1 and 2) , animals treated in this fashion had significantly reduced AP-1 activation in the liver as compared with non-GdCl 3 -treated animals also infected with Ad.Cu/ZnSOD (Fig. 5A, lanes 1 and 2) . These findings suggest that hCu/ZnSOD transgene-expressing Kupffer cells may be required for the full AP-1 induction. As a control for adequate Kupffer cell regeneration (during the 14-day window following GdCl 3 treatment), which is required for Cu/ZnSOD-mediated AP-1 induction in the liver, we also performed a second set of control experiments. In these control studies, animals were first treated with GdCl 3 for 3 consecutive days, and Kupffer cells were allowed to regenerate for 14 days before infection with Ad.Cu/ZnSOD and analysis of AP-1 activity 14 days later. If Kupffer cell regeneration had achieved levels required for the inductive AP-1 response, we would expect the AP-1 DNA-binding profile to be similar to that in animals infected with Ad.Cu/ZnSOD, but not treated with GdCl 3 . As seen in Fig. 5C (lanes 3 and 4) , this was indeed the case; a 14-day regeneration period was sufficient to allow for inductive AP-1 responses following infection with Ad.Cu/ZnSOD. Furthermore, colloidal carbon uptake assays also confirmed recovery of Kupffer cell phagocytic activity by 14 days' post-GdCl 3 treatment (data not shown). In summary, these results suggest that Kupffer cells are necessary for the Cu/ZnSOD-induced AP-1 activity, and that infection of Kupffer cells with Ad.Cu/ZnSOD is also required for the full AP-1 response.
To conclusively address whether recombinant adenovirus was infecting both hepatocytes and Kupffer cells in the liver, immunofluorescent colocalization studies of an adenovirally encoded ␤-galactosidase reporter gene and a Kupffer cellspecific marker were performed on frozen liver sections. Results presented in Fig. 5D-5F clearly demonstrate that at the high doses of recombinant adenovirus used in these studies, both Kupffer cells and hepatocytes were readily infectable and expressed the reporter transgene.
To further substantiate findings that Kupffer cells are involved in Cu/ZnSOD redox activation of AP-1, we next sought to evaluate the activity of Kupffer cells using an in vivo colloidal carbon phagocytic uptake assay. Studies presented in -4) , or Ad.Cu/ZnSOD infection without I/R (lanes 5-8) . Control PBS-injected animals were also evaluated in the absence of I/R injury (lanes 9-12) . I/R injury was performed by 60 minutes of ischemia and 3 hours of reperfusion. In Cu/ZnSOD experiments, animals were infected with Ad.Cu/ZnSOD 2 weeks before the preparation of nuclear extracts. These studies indicate that cJun and JunD are the predominant components of activated AP-1 complexes in both I/R injured-and Cu/ZnSODexpressing livers. AP-1 and supershifted (*) bands are marked by arrows to the left of the gel. The activation of JNK-1 following I/R injury and Cu/ZnSOD overexpression in the absence of I/R injury was compared. (B) Results shown in vitro kinase assays using GST-cJun as a substrate in the presence of g-ATP 32 . Samples shown on the SDS-PAGE autoradiogram include: (lanes 1 and 2) PBS mock-infected animals with no I/R injury, (lanes 3-5) PBS mock-infected animals with 60 minutes of ischemia and the indicated times (min) of reperfusion above each lane, and (lanes 6-11) Ad.Cu/ZnSOD-infected animals with no I/R injury harvested at the indicated postinfection times (days) above each lane.The phosphorylated GST-cJun bands are indicated by arrows to the left of the gel. GdCl 3 treatment. These studies confirm that Kupffer cell ablation was successful using our protocols. Furthermore, these studies substantiate a link between AP-1 induction by Cu/ ZnSOD and increased activation of Kupffer cells. Lastly, to confirm that H 2 O 2 produced by Cu/ZnSOD expression was responsible for the increased activated state of Kupffer cells, experiments were performed in livers coinfected with Ad.Cu/ ZnSOD and Ad.Catalase. Results from this analysis clearly demonstrate that catalase expression can attenuate (26-fold; P Ͻ .001) Cu/ZnSOD-induced phagocytic activity in the liver, as compared with livers infected with Ad.Cu/ZnSOD alone. Catalase-mediated effects on Kupffer cell phagocytic activity were not limited to Cu/ZnSOD-infected livers, but also reduced colloidal carbon uptake 5.6-and 7.8-fold in uninfected and Ad.LacZ-infected livers, respectively. These results suggest that perhaps normal levels of H 2 O 2 , mediated by endogenous Cu/ZnSOD activity, also play a role in baseline Kupffer cell phagocytic activity. In summary, the in vivo colloidal carbon uptake assays have demonstrated a direct correlation between increased Kupffer cell phagocytic activity and increased activity of AP-1 under the various conditions that modulate the intracellular redox state.
Kupffer Cells May Synergistically Activate AP-1 in Hepatocytes
Through Secreted Factors. Results thus far have suggested that Cu/ZnSOD overexpression in Kupffer cells is required for full activation of AP-1. However, it is still unclear whether Cu/ ZnSOD overexpression in both Kupffer cells and hepatocytes can induce AP-1, or whether Kupffer cells play a stimulatory role in the activation of hepatocellular AP-1. Although the data suggest that adenovirally mediated transgene expression occurs in both cellular populations, it remains possible that Cu/ZnSOD overexpression in Kupffer cells is capable of inducing AP-1 in non-transgene-expressing hepatocytes through a paracrine mechanism. To begin to elucidate potential mechanistic interactions between Kupffer cells and hepatocytes that might influence AP-1 induction in the setting of Cu/ZnSOD overexpression, we performed in vitro reconstitution experiments with a hepatocyte (TIB) and a "Kupffer celllike" macrophage (RAW) cell line. Studies evaluating adenoviral infection of both TIB and RAW cells clearly demonstrate a selective induction of AP-1 by overexpression of hCu/ ZnSOD, but not hMnSOD or LacZ (Fig. 7A) . These studies suggest that both hepatocytes and Kupffer cells likely have the ability to induce AP-1 in the setting of high-level Cu/ZnSOD expression. However, the level of induction appeared to be lower than that seen in the liver following overexpression of Cu/ZnSOD. We next sought to evaluate whether Cu/ZnSODinduced macrophages secrete factors that might impart a synergistic activation of AP-1 in hepatocytes through a paracrine mechanism. These studies, presented in Fig. 7B , demonstrated several interesting findings. First, treatment of uninfected TIB cells with conditioned media from Ad.Cu/ZnSODinfected RAW cells led to induction of AP-1 at moderate levels (compare lanes 1 and 3) . This induction was dependent of To evaluate whether Cu/ZnSOD production of H 2 O 2 was responsible for the induction of AP-1, EMSA were performed to evaluate AP-1 DNA binding (A) on nuclear extracts harvested from athymic mice infected with either Ad.Cu/ ZnSOD alone ( lanes 2 and 3) ; Ad.Cu/ZnSOD and Ad.Catalase together ( lanes  4 and 5) ; or Ad.Catalase alone (lanes 6 and 7) . An uninfected control liver is shown in lane 1. All infections were performed 2 weeks before harvesting of nuclear extracts, and equal titers of virus were used in all infections, as outlined in Materials and Methods. The positions of AP-1 and free probe are indicated to the left of the gel by arrows. To confirm the expression of catalase in these studies, native acrylamide Western blots were performed (B) on liver cell lysates harvested from athymic mice infected with either Ad.Cu/ZnSOD alone ( lanes 1 and 2) ; Ad.Cu/ZnSOD and Ad.Catalase together ( lanes 3 and 4) ; or Ad.Catalase alone (lanes 5 and 6) . The catalase-immunoreactive bands were detected by ECL chemiluminescence and are indicated to the left of the blot by an arrow.
Cu/ZnSOD transgene expression in RAW cells and was not observed when conditioned media from uninfected RAW cells were used (compare lanes 1-3) . Second, induction of AP-1 in Cu/ZnSOD-expressing TIB cells was much higher when they were exposed to conditioned media from Cu/ZnSOD-expressing, as compared with uninfected, RAW cells (compare lanes 4 and 5). Interestingly, exposure of Cu/ZnSOD-expressing TIB cells to conditioned media from uninfected RAW cells appeared to have an inhibitory effect on the baseline activation of AP-1 (compare lanes 4 and 6). In summary, these results suggest that maximal induction of AP-1 is achieved in Cu/ZnSOD-overexpressing hepatocytes following exposure to a Cu/ZnSOD-induced secreted factor from Kupffer cells. This secreted factor appears to also have the ability to induce AP-1 in the absence of hepatocellular Cu/ZnSOD overexpression, but at a lower level.
Reciprocal experiments evaluating whether TIB cells secrete a Cu/ZnSOD-inducible factor that affects the activa- tion of AP-1 in RAW cells were also performed. Exposure of RAW cells to TIB-conditioned media induced AP-1 regardless of whether TIB or RAW cells were overexpressing the Cu/ ZnSOD transgene (Fig. 7, lanes 7-11) . Despite the background induction caused by an unknown factor secreted by TIB cells, AP-1 levels were maximally induced in Ad.Cu/ ZnSOD-infected RAW cells that were treated with conditioned media from hCu/ZnSOD-expressing TIB cells (lanes 11 and 15). These findings support the notion that Cu/ZnSOD overexpression in both hepatocytes and Kupffer cells synergistically activates AP-1 through a paracrine mechanism involving an unknown secreted factor(s).
DISCUSSION
ROS activation of AP-1 has been demonstrated following numerous environmental stimuli. Both superoxides and H 2 O 2 have been implicated in these mechanisms of AP-1 activation. 3, 42, 44, 46 Of fundamental interest to the present study is why ectopic expression of MnSOD, but not Cu/ZnSOD, is capable of protecting livers from I/R injury, and more effectively attenuating AP-1 activation. Studies demonstrating that ectopic expression of Cu/ZnSOD, but not MnSOD, constitutively activated AP-1 in the absence of I/R were pivotal to refining our hypotheses for why these similar enzymes with different subcellular localizations could functionally provide widely different therapeutic effects following I/R. We hypothesized that H 2 O 2 produced by Cu/ZnSOD-mediated superoxide degradation may, in part, be responsible for elevated AP-1 activation in livers overexpressing Cu/ZnSOD. In support of this hypothesis, others have suggested that certain antioxidant chemicals can lead to the induction of AP-1 through the generation of H 2 O 2 and subsequent conversion to hydroxyl radicals. 45 We therefore sought to test whether coexpression of catalase could attenuate Cu/ZnSOD-mediated activation of FIG. 6 . Kupffer cell endocytosis is increased by Cu/ZnSOD expression and inhibited by catalase. Mice were infected with various recombinant adenovirus vectors by tail-vein injection, and Kupffer cell phagocytic activity was evaluated using an in vivo colloidal carbon uptake assay as described in Materials and Methods. Animals were infected with viruses (singly or in combination) 2 weeks before analysis. Treatments with GdCl 3 (intravenously) were initiated on day 11 postinfection and continued for 3 consecutive days before uptake assays. Results in (A-I) represent 10-m dark-field photomicrographs of liver sections from the following treatment conditions: (A) PBS-injected, (B) Ad.LacZ-infected, (C) Ad.MnSOD-infected, (D) Ad.Cu/ZnSOD-infected, (E) Ad.LacZ-infected and treated with GdCl 3 , (F) Ad.Cu/ZnSOD-infected and treated with GdCl 3 , (G) Ad.Catalase-infected, (H) Ad.Catalase and Ad.LacZ-coinfected, and (I) Ad.Catalase and Ad.Cu/ZnSOD-coinfected. Colloidal carbon uptake by Kupffer cells is indicated by white grains under dark-field optics. Morphometric quantification using NIH image was performed to determine the percent area of colloidal carbon in the livers from 4 independent animals. Five sections were quantitated for each animal. Results from this analysis are depicted in (J) and give the mean (ϮSEM) percent area of the liver with colloidal carbon uptake.
AP-1 in the liver. These studies confirmed our original hypothesis and demonstrated that coexpression of catalase could significantly reduce AP-1 activation mediated by overexpression of Cu/ZnSOD. Catalase expression alone had no effect on the baseline levels of AP-1 activation in the liver. The fact that catalase coexpression could not completely inhibit Cu/ZnSOD-induced AP-1 activation may result from the fact that human catalase expressed from the recombinant adenoviral vector used in these studies resides predominantly in the peroxisomes, 36 and peroxide clearance would likely occur by diffusion into this compartment. However, Cu/ZnSOD has also been suggested by others to reside predominantly in a nonperoxisomal compartment. 21, 22 Despite these considerations, our data support the conclusion that H 2 O 2 generated by overexpression of Cu/ZnSOD mediates AP-1 activation in the liver.
AP-1 activation in the liver following I/R injury has been predominantly thought to occur via the JNK/SAPK pathway. 39, 41, 47 Our results demonstrating that activated AP-1 complexes in the liver induced by Cu/ZnSOD expression are similar in composition (containing c-Jun and JunD) to those following I/R injury 39 suggest that similar pathways (i.e., JNK/ SAPK) may be activated in both cases. However, studies directly evaluating JNK-1 activity proved otherwise. JNK-1 activity, which increases following I/R injury in the liver, remained unchanged in the presence of ectopic Cu/ZnSOD expression. These findings suggest that AP-1 activation by H 2 O 2 produced from Cu/ZnSOD is a functionally distinct pathway from that of JNK activation. Differences between the ability of MnSOD and Cu/ZnSOD to attenuate AP-1 activation following I/R injury could result from the relative abundance of other ROS clearance enzymes in mitochondrial and cytoplasmic compartments responsible for degradation of the SOD product, H 2 O 2 . Two enzymes responsible for H 2 O 2 clearance in these 2 cellular compartments are GPX and catalase. Thus, a higher capacity for degrading H 2 O 2 in mitochondria could in part account for the functional differences between these 2 SOD isoforms.
The liver is composed of several cell types including hepatocytes, Kupffer cells, and endothelial cells. All of these cell FIG. 7 . Cu/ZnSOD expression in hepatocytes and macrophages synergistically activates AP-1. Induction of AP-1 was evaluated by EMSA following infection of TIB (hepatocyte) and RAW (macrophage) cells with Ad.MnSOD, Ad.Cu/ZnSOD, or Ad.LacZ as described in Materials and Methods (A). To evaluate potential synergistic mechanisms of AP-1 activation between hepatocytes and macrophages, reconstitution experiments were performed by treating both Ad.Cu/ZnSOD-infected and uninfected TIB cells (T) with conditioned media from Ad.Cu/ZnSOD-infected or uninfected RAW cells (R) (lanes 1-6) . Similarly, Ad.Cu/ZnSOD-infected and uninfected RAW cells were treated with conditioned media from Ad.Cu/ZnSOD-infected or uninfected TIB cells (lanes [7] [8] [9] [10] [11] [12] . Conditions used for infection and preparation of conditioned media are described in Materials and Methods. Cell line 1 represents the cell type used for preparation of nuclear extracts for AP-1 EMSA analysis, while cell line 2 represents the cell type of origin for condition media used to treat cell line 1. The Ϯ below each cell type indicates whether the cells were preinfected with Ad.Cu/ZnSOD before analysis or harvesting of conditioned media. Uninfected TIB and RAW cells not treated with conditioned media are in lanes 1 and 7, respectively. Lane 13 is a reference control for AP-1 activation in the liver following I/R injury. Lanes 14 and 15 are shorter exposures of lanes 10 and 11, respectively. The positions of AP-1 and free probe are indicated to the left of the gel by arrows.
types may play important roles in redox regulation of signal transduction pathways in the liver. A recent report has implicated exogenous and endogenous H 2 O 2 with increased Kupffer cell phagocytic activity. 48 Given that H 2 O 2 production by ectopic expression of Cu/ZnSOD is implicated in the activation of AP-1, we sought to determine whether Kupffer cells might be a key cell type responsible for increased AP-1 activity. Immunofluorescent localization of recombinant adenovirally derived ␤-galactosidase demonstrated that Kupffer cells are infectable in vivo and thus could have altered function invoked by Ad.Cu/ZnSOD. Studies demonstrating that GdCl 3 ablation of Kupffer cells significantly reduced (4-fold; P Ͻ .001) the level of AP-1 activation in livers expressing Cu/ ZnSOD support the involvement of this cell type in this activation pathway. However, the fact that AP-1 induction in Cu/ ZnSOD-overexpressing livers remained significantly above background levels in the absence of Kupffer cells also suggests that transgene expressing hepatocytes may also contribute to part of the AP-1 response. Key studies attempting to elucidate the involvement of Kupffer cells and hepatocytes in the inductive AP-1 response by Cu/ZnSOD used timed adenoviral infection in livers conditionally depleted of Kupffer cells. Following regeneration of non-transgene-expressing Kupffer cells, livers expressing hCu/ZnSOD primarily only in hepatocytes had a significantly reduced AP-1 induction in comparison with controls reinfected with Ad.Cu/ZnSOD after Kupffer cells regenerated. These key experiments demonstrate that Cu/ZnSOD transgene expression in Kupffer cells is also required for the full induction of AP-1. The question as to whether Cu/ZnSOD transgene expression in hepatocytes is also required remains to be determined. However, livers expressing hCu/ZnSOD primarily in hepatocytes demonstrate elevated AP-1 activity clearly above background levels. Although this level is below that in the presence of Cu/ZnSODexpressing Kupffer cells, it does suggest that Cu/ZnSOD may also directly activate AP-1 in hepatocytes to some extent. Currently, we hypothesize that Cu/ZnSOD-overexpressing Kupffer cells may amplify the AP-1 activation in hepatocytes through a paracrine mechanism. Given the ratio of hepatocytes to Kupffer cells in the liver, it appears that some level of Kupffer cell-mediated activation of AP-1 in hepatocytes must occur to produce the level of AP-1 seen in total liver nuclear extracts. Whether the majority of this hepatocyte activation occurs through a cytokine secreted by Kupffer cells or increased superoxide production by Kupffer cells remains to be established.
In vitro reconstitution studies using conditioned media and Ad.Cu/ZnSOD infection in hepatocyte (TIB) and macrophage (RAW) cell lines shed some insights into the above mechanistic questions. Findings from these studies clearly demonstrated that Ad.Cu/ZnSOD infection could induce AP-1 to moderate levels in both cell types. However, the level of AP-1 induction in TIB cells was significantly enhanced by exposure to conditioned media from Ad.Cu/ZnSOD-infected RAW cells. This was not seen when uninfected RAW cell-conditioned media were used. Although this induction was independent of Cu/ZnSOD overexpression in TIB cells, the level of induction was far greater following Ad.Cu/ZnSOD infection. Such findings suggest that macrophages (and perhaps also Kupffer cells) are capable of synergistically inducing AP-1 activation in hepatocytes in a Cu/ZnSOD-dependent fashion. Reciprocal experiments treating RAW cells with TIB cellconditioned media were somewhat less clear as a result of the induction of AP-1 in a Cu/ZnSOD-independent fashion. However, these studies also demonstrated that maximal AP-1 induction in macrophages was achieved when both cell types were infected with Ad.Cu/ZnSOD. Support for the notion that overexpression of Cu/ZnSOD in Kupffer cells alters the activated state of this cell type was also demonstrated by significantly increased colloidal carbon uptake in the liver, as compared with control uninfected livers or those expressing MnSOD or LacZ. The fact that adenovirally expressed hMnSOD and hCu/ZnSOD correctly partitioned to either mitochondrial or cytoplasmic subcellular fractions, respectively, suggests that subcellular redox states may be strictly partitioned in Kupffer cells to control their activation. Furthermore, GdCl 3 ablation of Kupffer cells, or coexpression of catalase, in livers expressing Cu/ZnSOD also significantly attenuated colloidal carbon uptake in the liver suggests that increased H 2 O 2 production by Cu/ZnSOD in Kupffer cells may be responsible for both increased AP-1 and phagocytic activation. The link between increased phagocytic activation of Kupffer cells and AP-1 induction remains unknown, but could be the result of AP-1 transcriptional induction of scavenger receptors.
In summary, the present study has begun to elucidate functional differences in the ability of MnSOD and Cu/ZnSOD to protect the liver from I/R injury. These differences appear to be centered around the ability of ectopic Cu/ZnSOD expression to induce AP-1 activity through a JNK-independent pathway in the liver. The mechanism of AP-1 induction by Cu/ ZnSOD appears to require transgene-expressing Kupffer cells and the production of H 2 O 2 or a metabolite such as hydroxyl radicals. These functional changes in Kupffer cells also appear to induce AP-1 in hepatocytes through the action of a paracrine mechanism involving an unknown factor secreted by Kupffer cells. Although in vitro studies suggest that expression of Cu/ZnSOD in hepatocytes may not be required for AP-1 induction by Cu/ZnSOD-expressing Kupffer cells, they do suggest some level of synergistic AP-1 activation dependent on Cu/ZnSOD expression in both cell types. Such findings have begun to elucidate important redox-sensitive pathways that control AP-1 activity in the liver and should be considered when developing gene therapies for I/R injury.
